secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086086
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Q2 2024 IGALMI net revenue up 141% YoY to $1.1M; net loss narrows to $8.3M
--------------------------------------------------------------------------------

- IGALMI net revenue $1.1M (+141% YoY, +90% sequentially) on increased psychiatric clinic contracting.
- Net loss $8.3M vs $53.5M in Q2 2023; operating cash used $23.2M; cash $56.3M at June 30.
- Planning SERENITY At-Home Phase 3 for BXCL501 in agitation with bipolar/schizophrenia; TRANQUILITY In-Care Phase 3 for Alzheimer's agitation.
- IGALMI PMR study showed no tachyphylaxis/tolerance/withdrawal; no serious adverse events reported.
- Received USPTO Notice of Allowance for new patent expiring 2043, expected as 11th Orange Book listing for IGALMI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924086086/0001104659-24-086086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924086086/tm2420782d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer